Human Papillomavirus (HPV) Vaccine

The FDA has approved the first vaccine for human papillomavirus, HPV. The vaccine covers four types of HPV which together cause 70% of cervical cancers and 90% of warts. Approximately 200 cases of cervical cancer are diagnosed in Minnesota every year.

Clinical trials suggest that the first vaccine, Gardasil, which is made by Merck, may be 100% effective against these specific types of HPV, with minimal side effects. Three doses are required, preferably before sexual debut and exposure to the virus.

• Human Papillomavirus Vaccine Report to the Minnesota Legislature 2008 (PDF: 308KB/28 pages)
  HPV vaccine report prepared by MDH for the Minnesota legislature, February 1, 2008.
  
  
• Human Papillomavirus Vaccine: What You Should Know
  Fact sheet with general information about HPV and the vaccine that can prevent it.
  
  
• HPV Vaccine Questions and Answers
  CDC fact sheet answering questions about the vaccine, including safety concerns, how long the vaccine will last, who should get the vaccine, cost, and what the vaccine won't protect people from. Attention: Non-MDH link
  
  
• HPV: Promoting Early Adolescent Vaccination (Health Plan Initiative) Attention: Non-MDH link
  The HPV performance improvement initiative is a collaborative effort by nine health plans contracted to provide quality improvement projects targeted at the Medicaid population in Minnesota. The goals of the initiative are to promote awareness of the HPV vaccination and to increase the percentage of females that receive vaccination. Learn more about the intervention strategies and resources available for providers on this site.
  
  
• Human Papillomavirus (HPV) Infection
  CDC information about HPV, a group of viruses that includes more than 100 strains or types. More than 30 of these viruses are sexually transmitted, causing genital HPV infection, or genital warts. Attention: Non-MDH link

• Standing Orders for Administering Human Papillomavirus Vaccine
  IAC's standing order template for healthcare providers to use when vaccinating adolescents and adults against HPV. Attention: Non-MDH link
  

• CDC’s Advisory Committee Recommends Human Papillomavirus Virus Vaccination
  The Advisory Committee on Immunization Practices (ACIP) recommends adding HPV vaccine to routine vaccination schedules. Attention: Non-MDH link
  
  
• Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  Epidemiology of HPV and associated diseases, description of the HPV vaccine, and recommendations for its use for vaccination among females aged 9--26 years in the United States. Attention: Non-MDH link
  
  
• HPV and HPV Vaccine - Information for Healthcare Providers
  CDC information for healthcare providers about HPV and the new HPV vaccine. Attention: Non-MDH link
  
  
• Vaccine May Help Prevent Cervical Cancer: No Substitute for Screening Now
  Update on HPV vaccine research and its potential from American Cancer Society. Attention: Non-MDH link
  
  
• The Potential of Human Papillomavirus Vaccines
  New England Journal of Medicine discussion of the new HPV vaccines. Attention: Non-MDH link
  

 Need Help Opening a PDF File?

If you have questions or comments about this page, use our IDEPC Comment Form or call 651-201-5414 (TTY: 651-201-5797) for the MDH Infectious Disease Epidemiology, Prevention and Control Division.